Seiffge, DJ;
Cancelloni, V;
Räber, L;
Paciaroni, M;
Metzner, A;
Kirchhof, P;
Fischer, U;
... Caso, V; + view all
(2024)
Secondary stroke prevention in people with atrial fibrillation: treatments and trials.
The Lancet Neurology
, 23
(4)
pp. 404-417.
10.1016/S1474-4422(24)00037-1.
![[thumbnail of Werring_R4_Stroke AF review_clean.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Werring_R4_Stroke AF review_clean.pdf Access restricted to UCL open access staff until 19 March 2025. Download (266kB) |
Abstract
Atrial fibrillation is one of the most common cardiac arrhythmias and is a major cause of ischaemic stroke. Recent findings indicate the importance of atrial fibrillation burden (device-detected, subclinical, or paroxysmal and persistent or permanent) and whether atrial fibrillation was known before stroke onset or diagnosed after stroke for the risk of recurrence. Secondary prevention in patients with atrial fibrillation and stroke aims to reduce the risk of recurrent ischaemic stroke. Findings from randomised controlled trials assessing the optimal timing to introduce direct oral anticoagulant therapy after a stroke show that early start (ie, within 48 h for minor to moderate strokes and within 4–5 days for large strokes) seems safe and could reduce the risk of early recurrence. Other promising developments regarding early rhythm control, left atrial appendage occlusion, and novel factor XI inhibitor oral anticoagulants suggest that these therapies have the potential to further reduce the risk of stroke. Secondary prevention strategies in patients with atrial fibrillation who have a stroke despite oral anticoagulation therapy is an unmet medical need. Research advances suggest a heterogeneous spectrum of causes, and ongoing trials are investigating new approaches for secondary prevention in this vulnerable patient group. In patients with atrial fibrillation and a history of intracerebral haemorrhage, the latest data from randomised controlled trials on stroke prevention shows that oral anticoagulation reduces the risk of ischaemic stroke but more data are needed to define the safety profile.
Archive Staff Only
 |
View Item |
